



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/517,328
Filing Date	12/09/2004
First Named Inventor	Jeffrey A. Smith
Art Unit	1623
Examiner Name	Ganapathy Krishnan
Attorney Docket Number	00789-05

Sheet 1 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	JIN-RUI DAI, et. al., "Zerumbone, an HIV-Inhibitory and Cytotoxic Sesquiterpene of Zingiber aromaticum and Z. zerumbet", (1997) Natural Product Letters, Vol. 10, pp. 115-118.	
	B	MASAAKI HAYASHI, et. al., "Big Mitogen-Activated Protein Kinase 1/Extracellular Signal-Regulated Kinase 5 Signaling Pathway is Essential for Tumor-Associated Angiogenesis", Cancer Research, (2005); 65: (17), Pgs. 7699-7706.	X
	C	M.W. JACKSON, et. al., "Hdm2 Nuclear Export, Regulated by Insulin-Like Growth Factor-I/MAPK/p90Rsk Signaling, Mediates the Transformation of Human Cells", (2006) J. Biol. Chem. 281: 16814-20.	
	D	CHO YONG-YEON, et. al., "Ribosomal S6 Kinase 2 is a Key Regulator in Tumor Promoter-Induced Cell Transformation", (2007) Cancer Res. 67:8104-12.	
	E	ANA CUADRADO, et. al., "New Insights into RSK Activation and Hematopoietic Cancer", (2007) Cancer Cell 12, 187-189.	
	F	J.P. DAVID, et. al., "Essential Role of RSK2 in c-Fos-dependent Osteosarcoma Development", (2005) J. Clin. Invest. 115:664-72.	
	G	AMANDINE HURBIN, et. al., "Cooperation of Amphiregulin and Insulin-Like Growth Factor-1 Inhibits Bax- and Bad-Mediated Apoptosis via a Protein Kinase C-Dependent Pathway in Non-Small Cell Lung Cancer Cells", (2005), J. Biol. Chem. 280:19757-67.	
	H	RANA ANJUM, et. al., "The Tumor Suppressor DAP Kinase is a Target of RSK-Mediated Survival Signaling", (2005), Curr. Biol. 15:1762-7.	
	I	KAZUHIRO KATAYAMA, et. al., "Inhibition of the Mitogen-Activated Protein Kinase Pathway Results in the Down-Regulation of P-glycoprotein", (2007), Mol. Cancer Ther., 6:2092-102.	
	J	D.E. CLARK, (2005), "The Serine/Threonine Protein Kinase, p90 Ribosomal S6 Kinase, Is An Important Regulator of Prostate Cancer", Cancer Research, 65: 3108-16.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/517,328
				Filing Date	12/09/2004
				First Named Inventor	Jeffrey A. Smith
				Art Unit	1623
				Examiner Name	Ganapathy Krishnan
				Attorney Docket Number	00789-05
Sheet	2	of	2		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*